AbbVie Retained Earnings (Accumulated Deficit) 2010-2024 | ABBV
AbbVie retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- AbbVie retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-3.768B, a 310.62% decline year-over-year.
- AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
- AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.
- AbbVie retained earnings (accumulated deficit) for 2021 were $3.127B, a 196.4% increase from 2020.
AbbVie Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-1,000 |
| 2022 |
$4,784 |
| 2021 |
$3,127 |
| 2020 |
$1,055 |
| 2019 |
$4,717 |
| 2018 |
$3,368 |
| 2017 |
$5,459 |
| 2016 |
$4,378 |
| 2015 |
$2,248 |
| 2014 |
$535 |
| 2013 |
$1,567 |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
AbbVie Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-3,768 |
| 2024-03-31 |
$-2,384 |
| 2023-12-31 |
$-1,000 |
| 2023-09-30 |
$933 |
| 2023-06-30 |
$1,789 |
| 2023-03-31 |
$2,393 |
| 2022-12-31 |
$4,784 |
| 2022-09-30 |
$4,953 |
| 2022-06-30 |
$3,516 |
| 2022-03-31 |
$5,103 |
| 2021-12-31 |
$3,127 |
| 2021-09-30 |
$1,600 |
| 2021-06-30 |
$740 |
| 2021-03-31 |
$2,292 |
| 2020-12-31 |
$1,055 |
| 2020-09-30 |
$3,335 |
| 2020-06-30 |
$3,130 |
| 2020-03-31 |
$5,973 |
| 2019-12-31 |
$4,717 |
| 2019-09-30 |
$3,673 |
| 2019-06-30 |
$3,384 |
| 2019-03-31 |
$4,234 |
| 2018-12-31 |
$3,368 |
| 2018-09-30 |
$6,789 |
| 2018-06-30 |
$5,495 |
| 2018-03-31 |
$4,977 |
| 2017-12-31 |
$5,459 |
| 2017-09-30 |
$6,547 |
| 2017-06-30 |
$5,951 |
| 2017-03-31 |
$5,063 |
| 2016-12-31 |
$4,378 |
| 2016-09-30 |
$4,011 |
| 2016-06-30 |
$3,349 |
| 2016-03-31 |
$2,673 |
| 2015-12-31 |
$2,248 |
| 2015-09-30 |
$1,654 |
| 2015-06-30 |
$1,256 |
| 2015-03-31 |
$739 |
| 2014-12-31 |
$535 |
| 2014-09-30 |
$2,131 |
| 2014-06-30 |
$2,299 |
| 2014-03-31 |
$1,874 |
| 2013-12-31 |
$1,567 |
| 2013-09-30 |
$1,081 |
| 2013-06-30 |
$758 |
| 2013-03-31 |
$330 |
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$340.798B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
